Kiora Pharmaceuticals (KPRX)
(Real Time Quote from BATS)
$4.18 USD
-0.05 (-1.18%)
Updated Jul 15, 2024 11:12 AM ET
2-Buy of 5 2
A Value A Growth C Momentum A VGM
Income Statements
Fiscal Year end for Kiora Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 12 | 17 | 8 | 10 |
Income After Depreciation & Amortization | -13 | -12 | -17 | -8 | -7 |
Non-Operating Income | 0 | -1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -12 | -14 | -17 | -8 | -7 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -13 | -14 | -16 | -8 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -13 | -14 | -16 | -8 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -12 | -11 | -8 | -7 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 6 | 0 | 0 |
Income After Depreciation & Amortization | -13 | -12 | -17 | -8 | -7 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.54 | 0.08 | 0.03 | 0.01 | 0.01 |
Diluted EPS Before Non-Recurring Items | -24.21 | -166.97 | -637.26 | -637.26 | -802.88 |
Diluted Net EPS (GAAP) | -24.21 | -166.97 | -637.26 | -637.26 | -802.88 |
Fiscal Year end for Kiora Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 16.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 16.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.77 | 2.12 | 5.92 | 2.63 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 13.23 | -2.12 | -5.92 | -2.63 |
Non-Operating Income | NA | 0.23 | -0.02 | 0.16 | 0.02 |
Interest Expense | NA | 0.00 | 0.01 | 0.00 | 0.00 |
Pretax Income | NA | 13.45 | -2.18 | -5.76 | -2.61 |
Income Taxes | NA | 0.00 | 0.09 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | -0.53 | 0.53 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 13.45 | -2.27 | -5.76 | -2.61 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 13.45 | -1.74 | -6.29 | -2.61 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.89 | NA | 0.79 | 0.37 |
Diluted EPS Before Non-Recurring Items | NA | 3.42 | NA | -8.01 | -7.11 |
Diluted Net EPS (GAAP) | NA | 3.42 | -0.09 | -8.01 | -7.11 |